RXFP1

Relaxin receptor 1 · Q9HBX9 · RXFP1 on Sugi Atlas →

420,139 patent compounds predicted against RXFP1, 259,967 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ufenamate (SCHEMBL36095)	0.59	8/20
SCHEMBL61762	0.45	6/20
Theofibrate (SCHEMBL49272)	0.55	5/20
Dyphylline (SCHEMBL8192)	0.64	4/20
Etofenamate (SCHEMBL25152)	0.58	4/20
Mercaptopurine Anhydrous (SCHEMBL3893)	0.46	4/20
Epinephrine (SCHEMBL40741)	1.00	3/20
Racepinephrine (SCHEMBL40742)	1.00	3/20
SCHEMBL34880	0.68	3/20
SCHEMBL34856	0.62	3/20
Flutolanil (SCHEMBL18555)	0.59	3/20
Dimethazan (SCHEMBL49056)	0.59	3/20
Dibucaine (SCHEMBL34473)	0.58	3/20
Dibucaine (SCHEMBL31303)	0.57	3/20
Diphenhydramine (SCHEMBL49392)	0.55	3/20
SCHEMBL12182	0.53	3/20
SCHEMBL10945	0.52	3/20
SCHEMBL64687	0.50	3/20
SCHEMBL29143	0.49	3/20
SCHEMBL1124	0.48	3/20

Clinical trials — most relevant to RXFP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
A Study Of The Usage Of Statins In A Community Heart Failure Population	PHASE4	COMPLETED
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD	PHASE4	UNKNOWN
Blood Pressure Outcomes With Liraglutide Therapy	PHASE4	COMPLETED
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.	PHASE3	UNKNOWN
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure	PHASE2/PHASE3	COMPLETED
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis	PHASE2/PHASE3	RECRUITING
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET	PHASE2/PHASE3	COMPLETED
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	PHASE2/PHASE3	COMPLETED
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function	PHASE3	COMPLETED
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients	PHASE2/PHASE3	UNKNOWN
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function	PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia	PHASE2	RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)	nan	COMPLETED
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Effect of Supplement on Appetite and GLP-1	nan	COMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING
Relaxin Measurement in Different Endometrial Preparation Approaches for Frozen Embryo Transfer	nan	RECRUITING
Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Purinergic Signaling and the Postmenopausal Heart	nan	RECRUITING
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	nan	RECRUITING
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy	nan	COMPLETED
The Effect of Weekly Semaglutide Treatment on Energy Expenditure	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RXFP1 binder may also engage these)

Protein	Name	Similarity
Q6R6I6	—	1.000	Q6R6I6 →
Q5R5V8	—	1.000	Q5R5V8 →
Q6R6I7	—	0.994	Q6R6I7 →
RXFP2	Relaxin receptor 2	0.983	landscape →
Q5XM32	—	0.983	Q5XM32 →
P79763	—	0.976	P79763 →
Q91ZZ5	—	0.975	Q91ZZ5 →
Q6YNB6	—	0.975	Q6YNB6 →
Q6R6L8	—	0.975	Q6R6L8 →
P16582	—	0.974	P16582 →
P20395	—	0.973	P20395 →
P49059	—	0.972	P49059 →
A0N0X6	—	0.971	A0N0X6 →
Q9BGN4	—	0.971	Q9BGN4 →
LHCGR	Lutropin-choriogonadotropic hormone receptor	0.970	landscape →
F1MLX5	—	0.970	F1MLX5 →
Q61809	—	0.970	Q61809 →
Q5R482	—	0.969	Q5R482 →
P21463	—	0.969	P21463 →
TSHR	Thyrotropin receptor	0.969	landscape →
Q27987	—	0.969	Q27987 →
O02721	—	0.969	O02721 →
P35378	—	0.969	P35378 →
Q28585	—	0.968	Q28585 →
Q6QMG1	—	0.968	Q6QMG1 →
Q7ZTV5	—	0.968	Q7ZTV5 →
B0BLW3	—	0.968	B0BLW3 →
Q28005	—	0.967	Q28005 →
Q66HV9	—	0.967	Q66HV9 →
Q95179	—	0.967	Q95179 →